Study examines patient-reported outcomes for opioid dependence treatment with weekly or monthly subcutaneous depot buprenorphine versus daily sublingual buprenorphine.
The watchdog says its projections on clearing the backlog assumes hospitals will be able to operate at 11% above pre-pandemic volumes in the coming years.
